A Case-Control Study of Gynecomastia in HIV-1-Infected Patients Receiving HAART

AIDS Reader

Volumn 14, Issue 1, 2004, Pages 23-24+29

  Rahim, Sibtain ^a   Ortiz, Olivia ^a   Maslow, Melanie ^a   Holzman, Robert ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Efavirenz; Gynecomastia; HAART; HIV AIDS

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; EFAVIRENZ; LOPINAVIR; SAQUINAVIR; TESTOSTERONE;

ADULT; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; GYNECOMASTIA; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; LIVER DYSFUNCTION; LOGISTIC REGRESSION ANALYSIS; LYMPHOCYTE COUNT; OUTCOMES RESEARCH; RETROSPECTIVE STUDY; RISK FACTOR; TESTOSTERONE BLOOD LEVEL;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; GYNECOMASTIA; HIV INFECTIONS; HIV-1; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEW YORK CITY; OXAZINES; RISK FACTORS; TESTOSTERONE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0345867154     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Wilson JD. Endocrine disorders of the breast. Gynecomastia. In: Isselbacher KJ, Braunwald E, Wilson JD, et al, eds. Harrison's Principles of Internal Medicine. 13th ed. New York: McGraw Hill; 1994:2037-2039.
2. Nydick M, Bustos J, Dale JH Jr, Rawson RW. Gynecomastia in adolescent boys. JAMA. 1961;178:449-454.
3. Lee PA. The relationship of concentrations of serum hormones to pubertal gynecomastia. J Pediatr. 1975;86:212-215.
4. Moore DC, Schlaepfer LV, Paunier L, Sizonenko PC. Hormonal changes during puberty, V: transient pubertal gynecomastia: abnormal androgen-estrogen ratios. J Clin Endocrinol Metab. 1984;58:492-499.
5. Andersen JA, Gram JB. Male breast at autopsy. Acta Pathol Microbiol Immunol Scand. 1982;90:191-197.
6. Bidlingmaier F, Knorr D. Plasma testosterone and estrogens in pubertal gynecomastia. Z Kinderheilkd. 1973;115:89-94.
7. Ismail AA, Barth JH. Endocrinology of gynaecomastia. Ann Clin Biochem. 2001;38:596-607.
8. Braunstein GD. Gynecomastia. N Engl J Med. 1993; 328:490-495.
9. Rose LI, Underwood RH, Newmark SR, et al. Pathophysiology of spironolactone-induced gynecomastia. Ann Intern Med. 1977;87:398-403.
10. Grosso DS, Boyden TW, Pamenter RW, et al. Ketoconazole inhibition of testicular secretion of testosterone and displacement of steroid hormones from serum transport proteins. Antimicrob Agents Chemother. 1983;23:207-212.
11. Rifka SM, Pita JC, Vigersky RA, et al. Interaction of digitalis and spironolactone with human sex steroid receptors. J Clin Endocrinol Metab. 1978;46:338-344.
12. Wilson JD, Aiman J, MacDonald PC. The pathogenesis of gynecomastia. Adv Intern Med. 1980;25:1-32.
13. Coen P, Kulin H, Ballantine T, et al. An aromatase-producing sex-cord tumor resulting in prepubertal gynecomastia. N Engl J Med. 1991;324:317-322.
14. Hemsell DL, Edman CD, Marks JF, et al. Massive extraglandular aromatization of plasma androstenedione resulting in feminization of a prepubertal boy. J Clin Invest, 1977;60:455-464.
15. Gottswinter JM, Korth-Schutz S, Ziegler R. Gynecomastia caused by estrogen containing hair lotion. J Endocrinol Invest. 1984,7:383-386.
16. DiRaimondo CV, Roach AC, Meador CK. Gynecomastia from exposure to vaginal estrogen cream. N Engl J Med. 1980;302:1089-1090.
17. Boyden TW, Pamenter RW. Effects of ethanol on the male hypothalamic-pituitary-gonadal axis. Endocr Rev. 1983;4:389-395.
18. Caeiro JP, Visnegarwala F, Rodriguez-Barradas MC. Gynecomastia associated with indinavir therapy. Clin Infect Dis. 1998;27:1539-1540.
19. Melbourne KM, Brown SL, Silverblatt FJ. Gynecomastia with stavudine treatment in an HIV-positive patient. Ann Pharmacother. 1998;32:1108.
20. Toma E, Therrien R. Gynecomastia during indinavir antiretroviral therapy in HIV infection. AIDS. 1998;12:681-682.
21. Schurmann D, Bergmann F, Ehrenstein T, Padberg J. Gynaecomastia in a male patient during protease inhibitor treatment for acute HIV disease. AIDS. 1998;12:2232-2233.
22. Peyriere H, Mauboussin JM, Rouanet L et al. Report of gynecomastia in five male patients during antiretroviral therapy for HIV infection. AIDS. 1999;13: 2167-2169.
23. Donovan B, Bodsworth NJ, Mulhali BP, Allen D. Gynecomastia associated with saquinavir therapy. Int J STD AIDS. 1999;10:49-50.
24. Caso J, Prieto Jde M, Casas E, Sanz J. Gynecomastia without lipodystrophy syndrome in HIV-infected men treated with efavirenz. AIDS. 2001;15: 1447-1452.
25. Mercie P, Viallard JF, Thiebaut R, et al. Efavirenz-associated breast hypertrophy in HIV-infected patients. AIDS. 2001;15:126-129.
26. Manfredi R, Calza L, Chiodo F. Gynecomastia associated with highly active antiretroviral therapy. Ann Pharmacother. 2001;35:438-439.
27. Aquilina C, Viraben R. Gynecomastia in a male patient during stavudine and didanosine treatment for HIV infection. Int J STD AIDS. 2001;12:481-482.
28. Qazi NA, Morlese JF, King DM, et al. True gynecomastia, another manifestation of immune reconstitution disease? Int J STD AIDS. 2002;13:59-65.
29. Qazi NA, Morlese JF, King DM, et al, Gynecomastia without lipodystrophy in HIV-1 seropositive patients on efavirenz: an alternative hypothesis. AIDS. 2002;16:506-507.
30. Benveniste O, Simon A, Herson S. Successful percutaneous dihydrotestosterone treatment of gynecomastia occurring during highly active antiretroviral therapy: four cases and a review of the literature. Clin Infect Dis. 2001;33:891-893.
31. Evans DL, Pantanowitz L, Dezube BJ, Aboulafia DM. Breast enlargement in 13 men who were sero-positive for human immunodeficiency virus. Clin Infect Dis. 2002;35:1113-1119.
32. Piroth L, Grappin M, Petit JM, et al. Incidence of gynecomastia in men infected with HIV and treated with highly active antiretroviral therapy. Scand J Infect Dis. 2001;33:559-560.
33. Shevitz A, Wanke CA, Falutz J, Kotler DP. Clinical perspectives on HIV-associated lipodystrophy syndrome: an update. AIDS. 2001;15:1917-1930.
34. Mallon PWG, Cooper DA, Carr A. HIV-associated lipodystrophy. HIV Med. 2001;2:166-173.
35. Ghany M, Hoofnagle JH. Approach to the patient with liver disease. In: Braunwald E, Fauci AS, Kasper DL, et al, eds. Harrison's Principles of Internal Medicine. 15th ed. New York; McGraw Hill; 2001:1707-1710.
36. Dupont WD, Plummer WD. PS power and sample size program available for free on the Internet. Control Clin Trials 1997;18:274.
37. Dean AG, Dean JA, Coulombier D, et al. EpiInfo, Version 6.04a, a word-processing, database, and statistics program for public health on IBM-compatible microcomputers. Atlanta: Centers for Disease Control and Prevention; July 1996.